CLINICAL TRIAL: MIRAGE

这个子项目是许多研究子项目中的一个 由NIH/NCRR资助的中心赠款提供的资源。子项目和 研究者（PI）可能从另一个NIH来源获得了主要资金， 因此可以在其他CRISP条目中表示。所列机构为 研究中心，而研究中心不一定是研究者所在的机构。 在MINUS III中，研究人员将注意力转向越来越多的来自病理学、流行病学和遗传学研究的证据，这些证据表明血管疾病的危险因素也会增加AD的风险。 然而，由于大多数流行病学研究缺乏神经影像学数据，目前尚不清楚血管危险因素与AD之间的明显关联是否通过脑缺血损伤，加速原发性阿尔茨海默病神经退行性过程或其他过程来治疗。 一些血管风险因素在非裔美国人和日裔美国人人群中比白人更普遍。 研究人员参与了血管功能和脑血管健康的其他指标，包括血压和脑结构成像MRI，以及这些种族人群对AD的易感性。 为了成功地实施该项目，将从美国、加拿大和德国的11个中心收集1000例符合NINCDS/ADRDA标准的可能或明确的AD患者的样本，包括500名白人、300名非洲裔美国人和200名日裔美国人，这些患者来自先证者和50岁以上的在世兄弟姐妹、配偶和子女。 将在先证者和同胞中评价DNA、血浆A β亚型和脑MRI。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. In MIRAGE III, the researchers are turning their attention to the growing body of evidence from pathological, epidemiological and genetic studies that risk factors for vascualar disease also enhance the risk of AD. However, since most epidemiological studies lack neuroimaging data, it is unclear whether the apparent association between vascular risk factors and AD is medicated via ischemic injury to the brain, acceleration of the primary Alzheimer's neurodegenerative process, or some other process. Some vascular risk factors are more prevalent in African American and Japanese American populations than in Caucasians. The researchers involved in vascular function and other indicators of cerebrovascular health including blood pressure and structural brain imaging (MRI), and susceptibility to AD in these ethnic groups. In order to carry out this project successfully, a sample of 1000 patients (500 Caucasians, 300 African Americans, 200 Japanese Americans) who meet NINCDS/ADRDA critera for probable or definite AD from 11 centers in the US, Canada and Germany will be collected from the probands and living siblings, spouses and children over the age of 50 years. DNA, plasma A beta isoforms and MRI of the brain will be evaluated in probands and siblings.